JLE

Hématologie

MENU

The epidemiology of myelodysplastic syndromes (MDS) and myeloproliferatif/myelodysplastic diseases (MDS/MPS) Volume 17, issue 2, Mars-Avril 2011

Figures

See all figures

Authors
Registre régional des hémopathies malignes de Basse-Normandie (RRHMBN), Caen, Laboratoire d’hématologie, CHU Côte de Nacre, Caen, Service d’hématologie clinique, CHU Côte de Nacre, Caen

The epidemiologic studies concerning the myelodysplastic syndromes (MDS) are limited and the crude incidence rate are heterogeneous, ranging from 1.0/100 000 in Japan and 9.3/100,000 in UK. We present the data from the Registre Régional des Hémopathies Malignes de Basse-Normandie (National Registry for Malignant Hemopathies in Basse-Normandie; RRHMBN). The myelodysplastic syndromes account for 13 % of all the new cases of malignant hemopathies occurring in patients residing in Basse-Normandie, at diagnosis. Refractory anaemia are common and account for half of the MDS cases. The world-standardized incidence rates (WSR) are 2.55/100,000±0.22 overall, 3.64±0.38 in man and 1.78±0.25 in woman (sex ratio: 2,04). The WSR increases with age: 1.75/100,000 in 50-54 years and 24.03 et 37.83/100,000 in 70-74 and 75-79 years, respectively. The differences in incidence can be explained by the heterogeneity of MDS, exhaustivity of the data collection, diagnostic criteria and the use of different classification over time. The epidemiologic data emerging from a regional and specialized registry are important in developing epidemiologic strategy and improving the knowledge in MDS.